AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety...

Growing Focus of Pharma Companies on Developing Drugs for COVID-19 Treatment to Foster the Growth of Antiviral Therapy Market during Pandemic - Exclusive Report [Pages-150] by Research Dive New York, USA, May 26, 2021 (GLOBE NEWSWIRE) -- The global antiviral therapy market is likely to witness an increase in the growth rate due to the COVID-19 pandemic. According to a latest report...

Global Antiviral Therapy Market to Surpass USD 79.8 Million and Rise at a CAGR of 6.7% Owing to COVID-19 Chaos by 2026 – Exclusive Report [150 Pages] by Research Dive New York, USA, Dec. 14, 2020 (GLOBE NEWSWIRE) -- According to a Research Dive published report, the global antiviral therapy market valued for $48.1 million in 2018 and is estimated to garner $79.8...